NDAORALSYRUP
Approved
Mar 1943
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
HYCODAN (hydrocodone bitartrate and homatropine methylbromide) by Teva is mu-opioid receptor, although it can interact with other opioid receptors at higher doses. First approved in 1943.
Drug data last refreshed 17h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYCODAN is an oral syrup combination of hydrocodone bitartrate (mu-opioid receptor agonist) and homatropine methylbromide (anticholinergic) approved in 1943 for cough suppression. Hydrocodone acts centrally on the cough center, while homatropine reduces secretions; the combination is used for symptomatic cough relief in patients who cannot tolerate or respond to non-opioid alternatives.
$0.235BPart D
LOE ApproachingDeclining
Approaching end-of-life with minimal claims volume signals a consolidating team focused on defending legacy market share against generic erosion.
Mechanism of Action
mu-opioid receptor, although it can interact with other opioid receptors at higher doses. The precise mechanism of action of hydrocodone and other opiates is not known; however, hydrocodone is believed to act centrally on the cough center. In excessive doses, hydrocodone will depress respiration.…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on HYCODAN offers limited career growth potential as the product approaches LOE with minimal commercial activity and no innovation pipeline. Roles are primarily defensive, focused on managing generic competition, ensuring compliance, and capturing residual market share in a declining segment.
Regulatory Affairs Specialist
Worked on HYCODAN at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.